Aroa Biosurgery
AROA Biosurgery Limited specializes in regenerative healing products for soft-tissue repair. It emphasizes the use of extracellular matrix (ECM) biomaterials in its offerings, giving it a niche position in the medical devices market. The company aims to improve healing outcomes and reduce healthcare costs, standing out through its innovative solutions and successful commercialization strategies.
Short position
Aroa Biosurgery (ASX:ARX) has 0.00% of its shares on issue reported as short positions as of 1 Oct 2026, or about 18 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.47% in August 2023. ARX is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Aroa Biosurgery (ARX) financials
Results, ratios and statements
Latest result
Year to 31 Mar 2026 (FY26) vs FY25, figures in NZD, the reporting currency
- Revenue
- 103.9MM (source: ASX (Markit))vs 84.7MM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 29 Sep 2026
- NPAT
- 4.7MM (source: ASX (Markit))vs −3.8MM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 29 Sep 2026
- EPS (basic)
- n/avs n/a (FY25)
- Rev YoY
- +22.6%FY
- EPS YoY
- n/aFY
- ASX (Markit)
Summary of Annual Report to Shareholders, 30 Jun 2026
Aroa Biosurgery (AROA) reported strong FY26 results, with total revenue increasing 23% to NZ$104 million and achieving a second consecutive year of positive normalised EBITDA of NZ$13 million. No dividend was declared for the period. For FY27, the company guides for total revenue between NZ$115 million and NZ$125 million, and normalised EBITDA of NZ$8 million to NZ$11 million.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 31 Mar 2026 (FY); no balance sheet aligned with this period; prices to 9 Oct 2026
- Gross margin
- n/a
- Operating margin
- n/a
- Net margin
- 4.5%
- FCF margin
- n/a
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- n/a
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (no share count we can vouch for)
- P/E
- n/a (reports in NZD)
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (NZD); market cap is in AUD. Sources: Yahoo Finance and ASX (Markit), as at 29 Sep 2026.
Financial statements
Figures in NZD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | 103.9MM (source: ASX (Markit)) | 84.7MM (source: ASX (Markit)) | 69.1MM (source: ASX (Markit)) | 63.4MM (source: ASX (Markit)) |
| NPAT | 4.7MM (source: ASX (Markit)) | −3.8MM (source: ASX (Markit)) | −10.6MM (source: ASX (Markit)) | −396.0KM (source: ASX (Markit)) |
| Shares | 345.5M | 344.9M | 344.2M | 343.1M |
- ASX (Markit)
Financial reports
The company's own filings, newest first
- Annual Report to ShareholdersAnnual Report30 Jun 2026via asx_announcements
- FY26 Appendix 4E and Full Year ResultsAnnual Results26 May 2026via asx_announcements
- FY26 Full Year Results PresentationFull Year Results26 May 2026via asx_announcements
- FY26 Full Year Results Presentation - CorrectionFull Year Results26 May 2026via asx_announcements
- Notification of Full Year Results WebinarFull Year Results19 May 2026via asx_announcements
- View PDFFinancial Report31 Dec 2025via smart_crawler
- View PFinancial Report31 Dec 2025via smart_crawler
- View PDFFinancial Report31 Dec 2025via smart_crawler
- View PDFFinancial Report31 Dec 2025via smart_crawler
- View PFinancial Report31 Dec 2025via smart_crawler
Showing 10 of 93 reports